Evidence map›Paper›PMID 29410663›Full record

ArticleFrontiers in immunology2017

A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation.

Thomas Eden, Stephan Menzel, Janusz Wesolowski, Philine Bergmann, Marion Nissen, Gudrun Dubberke, Fabienne Seyfried, Birte Albrecht, Friedrich Haag, Friedrich Koch-Nolte

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Development of Antibody and Nanobody Tools for P2X7.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Exploring cellular biochemistry with nanobodies.The Journal of biological chemistry · 2020
    Review
  16. Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors.Molecular therapy. Methods & clinical development · 2019
    Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Thomas EdenInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Stephan MenzelInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Janusz WesolowskiInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Philine BergmannInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Marion NissenInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Gudrun DubberkeInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Fabienne SeyfriedInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Birte AlbrechtInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Friedrich HaagInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Friedrich Koch-NolteInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Universität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanobodies (Nbs) are soluble, versatile, single-domain binding modules derived from the VHH variable domain of heavy-chain antibodies naturally occurring in camelids. Nbs hold huge promise as novel therapeutic biologics. Membrane proteins are among the most interesting targets for therapeutic Nbs because they are accessible to systemically injected biologics. In order to be effective, therapeutic Nbs must recognize their target membrane protein in native conformation. However, raising Nbs against membrane proteins in native conformation can pose a formidable challenge since membrane proteins typically contain one or more hydrophobic transmembrane regions and, therefore, are difficult to purify in native conformation. Here, we describe a highly efficient genetic immunization strategy that circumvents these difficulties by driving expression of the target membrane protein in native conformation by cells of the immunized camelid. The strategy encompasses ballistic transfection of skin cells with cDNA expression plasmids encoding one or more orthologs of the membrane protein of interest and, optionally, other costimulatory proteins. The plasmid is coated onto 1 µm gold particles that are then injected into the shaved and depilated skin of the camelid. A gene gun delivers a helium pulse that accelerates the DNA-coated particles to a velocity sufficient to penetrate through multiple layers of cells in the skin. This results in the exposure of the extracellular domains of the membrane protein on the cell surface of transfected cells. Repeated immunization drives somatic hypermutation and affinity maturation of target-specific heavy-chain antibodies. The VHH/Nb coding region is PCR-amplified from B cells obtained from peripheral blood or a lymph node biopsy. Specific Nbs are selected by phage display or by screening of Nb-based heavy-chain antibodies expressed as secretory proteins in transfected HEK cells. Using this strategy, we have successfully generated agonistic and antagonistic Nbs against several cell surface ecto-enzymes and ligand-gated ion channels.

Indexed as

antibody engineeringcDNA immunizationgenetic immunizationheavy-chain antibodymembrane proteinsnanobody

Identifiers

PMID29410663
PMCPMC5787055
OpenAlexW2791678513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.